Celldex Therapeutics (NASDAQ:CLDX) Announces Earnings Results

Celldex Therapeutics (NASDAQ:CLDX) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.22), FiscalAI reports. The company had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $1.53 million. Celldex Therapeutics had a negative return on equity of 39.67% and a negative net margin of 3,446.88%.

Celldex Therapeutics Trading Down 1.8%

Shares of Celldex Therapeutics stock traded down $0.54 during trading hours on Friday, reaching $30.10. The stock had a trading volume of 233,047 shares, compared to its average volume of 774,833. The stock’s 50 day moving average is $25.61 and its 200 day moving average is $25.43. Celldex Therapeutics has a twelve month low of $14.40 and a twelve month high of $31.31. The firm has a market capitalization of $2.00 billion, a PE ratio of -7.76 and a beta of 1.24.

Hedge Funds Weigh In On Celldex Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Wilmington Savings Fund Society FSB purchased a new position in Celldex Therapeutics during the third quarter worth approximately $42,000. Russell Investments Group Ltd. raised its stake in shares of Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 501 shares during the period. Quantbot Technologies LP acquired a new position in shares of Celldex Therapeutics during the 3rd quarter worth approximately $63,000. Kestra Advisory Services LLC purchased a new position in shares of Celldex Therapeutics during the 4th quarter valued at approximately $98,000. Finally, Headlands Technologies LLC acquired a new stake in Celldex Therapeutics in the 2nd quarter valued at $125,000.

Key Stories Impacting Celldex Therapeutics

Here are the key news stories impacting Celldex Therapeutics this week:

• Positive Sentiment: Stifel Nicolaus reaffirmed a Buy and raised its price target to $68 (from $58), signaling strong upside tied to Celldex’s pipeline and upcoming data catalysts. Stifel price target raise
• Positive Sentiment: Morgan Stanley maintained a Buy rating, noting early EMBARQ enrollment and 2026 data catalysts that support an attractive risk/reward profile for CLDX. Morgan Stanley note
• Neutral Sentiment: Analysts’ consensus remains a “Moderate Buy,” reflecting mixed views that balance developmental upside against short‑term financial weakness. Analyst consensus
• Neutral Sentiment: Short interest reporting appears anomalous (shows 0 shares), so it offers no clear bearish or bullish signal to traders at this time.
• Negative Sentiment: Celldex reported Q4/2025 EPS of ($1.22), missing consensus (~($1.00)), and revenue of $0.12M vs. ~$1.53M expected — a clear near-term negative catalyst that likely pressured the stock. Q4 results press release Detailed release
• Negative Sentiment: HC Wainwright’s updated model forecasts continued material losses (Q1 ’26 ≈ ($1.27), Q2 ’26 ≈ ($1.30), FY2027 ≈ ($5.53)), highlighting expectations for larger out-year dilution and operating losses — a longer‑term headwind for valuation. (research report summary)

Wall Street Analysts Forecast Growth

CLDX has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, January 21st. Barclays upped their target price on Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a research report on Wednesday, December 17th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $68.00 price target (up from $58.00) on shares of Celldex Therapeutics in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $44.20.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.